Literature DB >> 19128637

Retrospective review of 242 consecutive patients treated surgically for parotid gland tumours.

Farheen Mohammed1, Jamil Asaria, Richard J Payne, Jeremy L Freeman.   

Abstract

OBJECTIVE: To compare the trends and specific outcomes of patients treated surgically for parotid neoplasms between 1994 and 2005 with those of patients who were treated between 1985 and 1993 at Mount Sinai Hospital in Toronto and to identify preoperative indicators of malignancy.
METHODS: A retrospective chart review was performed that included all patients who received treatment from 1994 to 2005 at Mount Sinai Hospital. The results of this review was compared with those of another group at the same institution.
RESULTS: The study included 242 patients. Of these patients, 183 (75.6%) had benign neoplasms, 51 (21.1%) had malignant neoplasms, and 8 (3.3%) had inflammatory or lymphatic lesions. The most common associated symptoms were swelling (17.4%) and pain (16.5%). Only 5.8% of patients presented with facial weakness; however, the likelihood of malignancy was high (64.3%). Total parotidectomy was reserved for 26.4% of patients; the majority (68.2%) received a subtotal parotidectomy. Common postoperative complications included temporary facial nerve palsy (23.6%), Frey syndrome (12.4%), and salivary fistula (5.0%). Analysis of the correlation between fine-needle aspiration and final cytology revealed that fine-needle aspiration sensitivity and specificity were 60.0% and 96.1%, respectively. Comparison of these results with the other study at our institution revealed no significant differences in patient predictors or outcomes.
CONCLUSIONS: These results were compared with those of a previous study conducted at the same institution between 1985 and 1993. There was no significant deviation from former trends. The presenting symptoms of facial nerve weakness and lymphadenopathy were found to be strong indicators of malignant disease. Facial pain was found not to be a reliable prognostic feature for malignancy.

Entities:  

Mesh:

Year:  2008        PMID: 19128637

Source DB:  PubMed          Journal:  J Otolaryngol Head Neck Surg        ISSN: 1916-0208


  7 in total

1.  Role of ultrasound in the assessment of benignity and malignancy of parotid masses.

Authors:  S Wu; G Liu; R Chen; Y Guan
Journal:  Dentomaxillofac Radiol       Date:  2011-11-24       Impact factor: 2.419

2.  [The incidence of Frey syndrome following parotidectomy: results of a survey and follow-up].

Authors:  A Neumann; D Rosenberger; O Vorsprach; S Dazert
Journal:  HNO       Date:  2011-02       Impact factor: 1.284

3.  Reoperation following the use of non-standardized procedures for malignant parotid tumors.

Authors:  Xiangmin Zhang; Xiangfu Zeng; Xiaolin Lan; Jing Huang; Keqing Luo; Keqiang Tian; Xiuhong Wu; Fufu Xiao; Shaojin Li
Journal:  Oncol Lett       Date:  2017-09-21       Impact factor: 2.967

Review 4.  Sensitivity, Specificity, and Posttest Probability of Parotid Fine-Needle Aspiration: A Systematic Review and Meta-analysis.

Authors:  C Carrie Liu; Ashok R Jethwa; Samir S Khariwala; Jonas Johnson; Jennifer J Shin
Journal:  Otolaryngol Head Neck Surg       Date:  2015-10-01       Impact factor: 3.497

5.  Use of 2-Octyl-Cyanoacrylate in surgical closing of Postparotidectomy salivary fistulas.

Authors:  Zoran Pesic; Nikola Buric; Ivica Vuckovic; Dragan Petrovic; Dragan Krasic; Andrija Cosic; Ivana Djokic
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-09-08       Impact factor: 2.503

6.  Microsurgical dissection of facial nerve in parotidectomy: a discussion of techniques and long-term results.

Authors:  Fabio Nicoli; Christopher D'Ambrosia; Davide Lazzeri; Georgios Orfaniotis; Pedro Ciudad; Michele Maruccia; Li Tzong Shiun; Bulent Sacak; Shih-Heng Chen; Hung-Chi Chen
Journal:  Gland Surg       Date:  2017-08

7.  [Radiotherapy : an option for refractory salivary fistulas].

Authors:  H Christiansen; H A Wolff; J Knauth; A Hille; H Vorwerk; C Engelke; R Rödel; R Laskawi
Journal:  HNO       Date:  2009-12       Impact factor: 1.284

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.